Extended-Release Formulations and Serotonin-Norepinephrine Reuptake Inhibition Advancing Major Depression Management
Managing chronic major depressive disorder (MDD) and treatment-resistant anxiety disorders is driving steady clinical demand across neuropsychiatric drug delivery platforms. Detailed analysis within the Venlafaxine Market report demonstrates how extended-release (XR) formulations of venlafaxine—a dual-acting serotonin-norepinephrine reuptake inhibitor (SNRI)—maintain steady plasma...
0 Comments 0 Shares 77 Views 0 Reviews